STAT+: National Resilience, startup hoping to reinvent drug manufacturing, to ‘wind down’ many of its facilities
National Resilience, a startup that has raised over $2 billion by promising to transform drug manufacturing, said it would “wind down” many of its facilities.
National Resilience, a startup that has raised over $2 billion by promising to transform drug manufacturing, said Monday that it would “wind down” many of its facilities.
But what remains of the firm has raised an additional $250 million from existing investors to continue to build its business and seek more capital.
Through a bit of financial engineering, an affiliate of the company that holds leases for six of the company’s manufacturing facilities is filing for bankruptcy. National Resilience itself is not filing for bankruptcy, a spokesperson said, and will continue operating facilities in Toronto and Ohio, where it manufactures GLP-1 drugs for Eli Lilly.
